Polynovo Ltd (ASX: PNV) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Polynovo Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$1.41 billion
P/E Ratio
804.00
Dividend Yield
0.00%
Shares Outstanding
690.23 million
Earnings per share
0.003
Dividend per share
N/A
Year To Date Return
21.45%
Earnings Yield
0.12%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Polynovo Ltd (ASX: PNV)
Latest News
Healthcare Shares
Up 9.2% in 1 day, is the Clinuvel Pharmaceuticals (ASX:CUV) share price a buy?
Growth Shares
2 exciting ASX growth shares to buy in September
Growth Shares
Polynovo and one more ASX growth share to buy in 2021
Share Market News
Polynovo share price falls despite government grant
Healthcare Shares
Up 38% in August, is the Mesoblast share price a buy?
⏸️ Shares to Watch
Polynovo and 2 more ASX 200 shares to watch this week
Best Shares
My top 5 ASX shares to buy in 2020
Share Gainers
Polynovo share price rockets higher on insider buying news
Share Gainers
Why Costa, Flight Centre, Polynovo, & Pointsbet shares are storming higher
Share Fallers
Polynovo share price sinks lower despite doubling sales in FY 2020
Healthcare Shares
Mesoblast share price on watch after US regulatory approval
Healthcare Shares
Down 37% in 2 days! Is the Mesoblast share price a buy?
Frequently Asked Questions
-
The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was listed on the ASX on 26 November 1998 and is headquartered in Melbourne.
-
No, the company does not historically pay dividends.
PNV ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Polynovo Ltd
PolyNovo Ltd (ASX: PNV) develops and commercialises innovative medical devices using its patented NovoSorb technology.
NovoSorb is a family of biocompatible polymers that are used in the treatment of burns and surgical wounds. They biodegrade into by-products that can be absorbed and excreted by the body. For example, its NovoSorb BTM (Biodegradable Temporising Matrix) can be used to temporarily close a wound and aid the body in generating new tissue.
PolyNovo’s products are sold across Australia and New Zealand, the United States, the United Kingdom, and Europe.
PNV Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 17 Apr 2024 | $2.04 | $0.03 | 1.49% | 836,390 | $2.01 | $2.07 | $2.00 |
| 16 Apr 2024 | $2.01 | $-0.14 | -6.51% | 1,354,761 | $2.11 | $2.12 | $2.01 |
| 15 Apr 2024 | $2.15 | $0.00 | 0.00% | 1,208,939 | $2.12 | $2.16 | $2.09 |
| 12 Apr 2024 | $2.15 | $-0.01 | -0.46% | 744,109 | $2.15 | $2.18 | $2.13 |
| 11 Apr 2024 | $2.16 | $-0.09 | -4.00% | 1,174,841 | $2.17 | $2.20 | $2.12 |
| 10 Apr 2024 | $2.25 | $0.01 | 0.45% | 1,024,514 | $2.24 | $2.26 | $2.22 |
| 09 Apr 2024 | $2.24 | $-0.01 | -0.44% | 842,512 | $2.26 | $2.29 | $2.22 |
| 08 Apr 2024 | $2.25 | $0.07 | 3.21% | 1,750,835 | $2.22 | $2.27 | $2.22 |
| 05 Apr 2024 | $2.18 | $0.03 | 1.40% | 1,006,652 | $2.11 | $2.18 | $2.10 |
| 04 Apr 2024 | $2.15 | $0.06 | 2.87% | 564,036 | $2.11 | $2.18 | $2.11 |
| 03 Apr 2024 | $2.09 | $-0.05 | -2.34% | 1,668,083 | $2.11 | $2.13 | $2.07 |
| 02 Apr 2024 | $2.14 | $-0.05 | -2.28% | 1,640,360 | $2.19 | $2.19 | $2.13 |
| 28 Mar 2024 | $2.19 | $0.05 | 2.34% | 1,108,859 | $2.15 | $2.20 | $2.14 |
| 27 Mar 2024 | $2.14 | $0.04 | 1.90% | 1,793,957 | $2.12 | $2.22 | $2.11 |
| 26 Mar 2024 | $2.10 | $-0.02 | -0.94% | 6,338,523 | $2.10 | $2.12 | $2.06 |
| 25 Mar 2024 | $2.12 | $-0.01 | -0.47% | 2,646,839 | $2.15 | $2.16 | $2.09 |
| 22 Mar 2024 | $2.13 | $-0.07 | -3.18% | 1,118,356 | $2.18 | $2.19 | $2.10 |
| 21 Mar 2024 | $2.20 | $0.06 | 2.80% | 2,071,350 | $2.19 | $2.24 | $2.17 |
| 20 Mar 2024 | $2.14 | $-0.05 | -2.28% | 1,883,237 | $2.21 | $2.25 | $2.12 |
| 19 Mar 2024 | $2.19 | $-0.16 | -6.81% | 2,478,168 | $2.37 | $2.39 | $2.17 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 31 Oct 2023 | Robyn Elliott | Buy | 32,000 | $38,080 |
On-market trade.
|
| 28 Jun 2023 | Robyn Elliott | Buy | 27,000 | $39,690 |
On-market trade.
|
| 08 Jun 2023 | David Williams | Buy | 22,500 | $36,000 |
On-market trade.
|
| 07 Jun 2023 | David Williams | Buy | 14,453 | $23,448 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr David Williams | Non-Executive DirectorNon-Executive Chairman | Feb 2014 |
Mr Williams was appointed as a Non-executive Director on 28 February 2014 and Chairman on 13 March 2014. Mr Williams is an experienced Director and investment banker with a track record in business development as well as in mergers and acquisitions and capital raising.
|
| Mr Bruce Rathie | Non-Executive Director | Feb 2010 |
Mr Rathie was appointed a Director of PolyNovo on 18 February 2010. He is an experienced Company Director with a finance and legal background. He practised as a partner in a legal firm and acted as Senior Corporate Counsel to Bell Resources Limited.
|
| Dr Robyn Elliott | Non-Executive Director | Oct 2019 |
Dr Elliott was appointed a Director of PolyNovo on 28 October 2019. Dr Elliott is currently Global Head, Strategic Portfolio Management at CSL Behring. Dr Elliott previously held Strategic Expansion and Quality Senior Director roles within CSL, was the Managing Director at IDT Australia and commenced her career at DBL Faulding.
|
| Mr Andrew Stuart Lumsden | Non-Executive Director | Jun 2021 |
Mr Lumsden was appointed a Director of PolyNovo on 4 June 2021. He has more than 20 years' experience locally and internationally. Mr Lumsden is currently Chief Executive Officer of Wellcom Worldwide Australasia having previously held the roles of Group Chief Financial Officer and Group Chief Operating Officer.
|
| Mr Leon Hoare | Non-Executive Director | Jan 2016 |
Mr Hoare was appointed a Director of PolyNovo on 27 January 2016. He is currently the Managing Director of Lohmann & Rauscher, Australia & New Zealand (ANZ), a private EU based medical device company. Previously he was Managing Director of Smith & Nephew ANZ (all divisions) until 2015. He served as President of Smith & Nephew's Asia-Pacific Advanced Wound Management (AWM) businesses for 5 years and was a member of the Global Executive Management for the AWM Division.
|
| Ms Christine Emmanuel-Donnelly | Non-Executive Director | May 2020 |
Ms Emmanuel-Donnelly was appointed a Director of PolyNovo on 13 May 2020. She has more than 30 years' local and international experience. She is Vice President of the Board of the Institute of Patent and Trade Mark Attorneys of Australia on Springboard Enterprises Life Sciences Council, is a non-executive director on the board of Medical Developments International and is a member of the Australian Institute of Company Directors.
|
| Mr Jan-Marcel Gielen | Chief Financial OfficerCompany Secretary | Dec 2018 |
-
|
| Mr Swami Raote | Chief Executive Officer | Jul 2022 |
-
|
| Swami Raote | Chief Executive Officer |
-
|
|
| Jan-Marcel Gielen | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 94,468,202 | 13.69% |
| J P Morgan Nominees Australia Pty Limited | 58,519,477 | 8.48% |
| Citicorp Nominees Pty Limited | 26,811,635 | 3.88% |
| Moggs Creek Pty Ltd (Moggs Creek Super A/C) | 19,010,112 | 2.75% |
| BNP Paribas Noms Pty Ltd (Drp) | 12,383,050 | 1.79% |
| Lateral Innovations Pty Ltd (Trust A/C) | 10,924,103 | 1.58% |
| National Nominees Limited | 8,413,960 | 1.22% |
| Mr Anthony Shane Kittel + Mrs Michele Therese Kittel (Kittel Family Super A/C) | 8,055,789 | 1.17% |
| BNP Paribas Nominees Pty Ltd (Ib Au Noms Retailclient Drp) | 5,909,896 | 0.86% |
| Sandhurst Trustees Ltd (Endeavor Asset Mgmt Mda A/C) | 5,739,049 | 0.83% |
| Netwealth Investments Limited (Wrap Services A/C) | 4,276,587 | 0.62% |
| Ms Simone Maree Beks | 4,185,095 | 0.61% |
| Mr Paul Gerard Brennan | 4,185,095 | 0.61% |
| Commonwealth Scientific And Industrial Research Organisation | 4,081,250 | 0.59% |
| Mr Matthew James Avery | 3,631,338 | 0.53% |
| Mrs Li-Hsien Tsai | 3,292,698 | 0.48% |
| Mr David Kenley | 3,139,855 | 0.45% |
| Dr Marcus James Dermot Wagstaff + Mrs Lara Kate Wagstaff | 3,072,166 | 0.45% |
| Mr Laurent Fossaert | 2,929,961 | 0.42% |
| MR CHRIS DAWBORN (HASKALI SUPER FUND A/C) | 2,870,271 | 0.42% |
